NasdaqGS:ACADBiotechs
Acadia Pharmaceuticals (ACAD) Margin Expansion To 36.5% Tests Bearish Earnings Narratives
ACADIA Pharmaceuticals (ACAD) capped FY 2025 with Q4 revenue of US$284 million and basic EPS of US$1.62, while trailing 12 month revenue reached about US$1.1 billion and basic EPS came in at US$2.32 as the company reported net profit margins of 36.5% over the last year, up from 23.6% the prior year. Over the past year, ACADIA has seen earnings grow 72.7% with a 5 year average earnings growth rate of 66.5% per year, and analysts currently expect earnings to grow about 8.2% per year alongside...